Bachul PJ, Gołębiewska JE, Basto L, et al. - Researchers examined the efficacy of the BETA-2 score in early prediction of graft decline and loss of insulin independence after islet allotransplantation. Based on clinical outcome, stratification of islet transplant procedures into 3 groups was done: long-term insulin independence without islet graft decline (group 1, N = 9), initial insulin independence with subsequent islet graft decline and loss of insulin independence (group 2, N = 13) and no insulin independence (group 3, N = 13). Posttransplantation, calculation of BETA-2 was done on day 75 and multiple times afterward for up to 145 months. With a sensitivity and negative predictive value of 100%, a BETA-2 score cut-off of 17.4 on day 75 posttransplantation distinguished between group 1 and groups 2 and 3. Furthermore, at any time point during follow-up, BETA-2 ≥ 17.4 indicated islet function requiring long-term insulin independence. While, in group 1, no fall in BETA-2 below 17.4 was observed, the score declined below 17.4 for all transplants from group 2 with subsequent loss of insulin independence. The reduction of BETA-2 below 17.4 prognosticated 9 (1.5-21) months in advance subsequent islet graft decline and loss of insulin independence. Findings seem to have important implications for posttransplant monitoring and patient care.